

Egalet's Guardian Technology receives US patent

21 February 2018 | News

Egalet Announces Issuance of New U.S. Patent for Guardian™ Technology



Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, has received a US patent for its proprietary Guardian Technology.

The patent covers the Guardian Technology two-component tablet architecture which provides precise drug delivery and can confer abuse-deterrent properties.

The United States Patent and Trademark Office (USPTO) have issued patent number 9,884,029 covering Egalet-002. The patent offers protection through March 2024.

Egalet has been granted a total of 20 US patents and 59 patents outside of the US that cover Guardian Technology and its product candidate